EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY
EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- xeomin
What it measured
Main measures
to verify efficay and safety of one treatment with BT-A in patients affected by primary or secondary and progressive SM or by other CID influencing arm spasticity.
SpasticitySafety
Who could take part
Progressive MS
Show the full criteria
Inclusion criteria
Inclusion: patients aged more then 18 affected by primary or secondary progressive SM or by other chronic inflammatory diseases of the CNS diagnosed 6 months before the beginning of the study;arm spasticity with 1 or more point for Modified Ashworth Scale ; ........... Exclusion: permanent contractures or severe atrophy in spastic arm; previous treatment with BT-A or with alccol/phenol injection or surgery;modification in madical therapy or rehabilitation therapy in the prevoious 3 months; treatment with intratecal baclofen or with drugs modulationg neuromuscolar trasmission; .......
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
to verify efficay and safety of one treatment with BT-A in patients affected by primary or secondary and progressive SM or by other CID influencing arm spasticity.
Loading reviews and guidelines…
History
Started
Nov 2007